» Articles » PMID: 17699549

Fibroblast Growth Factor 23 Impairs Phosphorus and Vitamin D Metabolism in Vivo and Suppresses 25-hydroxyvitamin D-1alpha-hydroxylase Expression in Vitro

Overview
Specialties Nephrology
Physiology
Date 2007 Aug 19
PMID 17699549
Citations 142
Authors
Affiliations
Soon will be listed here.
Abstract

Fibroblast growth factor-23 (FGF-23) is critical to the pathogenesis of a distinct group of renal phosphate wasting disorders: tumor-induced osteomalacia, X-linked hypophosphatemia, and autosomal dominant and autosomal recessive hypophosphatemic rickets. Excess circulating FGF-23 is responsible for their major phenotypic features which include hypophosphatemia due to renal phosphate wasting and inappropriately low serum 1,25(OH)2D concentrations. To characterize the effects of FGF-23 on renal sodium-phosphate (Na/P(i)) cotransport and vitamin D metabolism, we administered FGF-23(R176Q) to normal mice. A single injection (0.33 microg/g body wt) induced significant hypophosphatemia, 20 and 29% decreases (P < 0.001) in brush-border membrane (BBM) Na/Pi cotransport at 5 and 17 h after injection, respectively, and comparable decreases in the abundance of type IIa Na/P(i) cotransporter protein in BBM. Multiple injections (6, 12, and 24 mug/day for 4 days) induced dose-dependent decreases (38, 63, and 75%, respectively) in renal abundance of 1alpha-hydroxylase mRNA (P < 0.05). To determine whether FGF-23(R176Q) exerts a direct action on 1alpha-hydroxylase gene expression, we examined its effects in cultured human (HKC-8) and mouse (MCT) renal proximal tubule cells. FGF-23(R176Q) (1 to 10 ng/ml) induced a dose-dependent decrease in 1alpha-hydroxylase mRNA with a maximum suppression of 37% (P < 0.05). Suppression was detectable after 6 h of exposure and maximal after 21 h. In MCT cells, FGF-23(R176Q) suppressed 1alpha-hydroxylase mRNA and activated the ERK1/2 signaling pathway. The MAPK inhibitor PD98059 effectively abolished FGF-23-induced suppression of 1alpha-hydroxylase mRNA by blocking signal transduction via ERK1/2. These novel findings provide evidence that FGF-23 directly regulates renal 1alpha-hydroxylase gene expression via activation of the ERK1/2 signaling pathway.

Citing Articles

Evaluation of Bone Biomarkers in Renal Osteodystrophy.

Pichone A, Gomes C, Moreira C, Farias M, Leite Jr M Life (Basel). 2025; 14(12.

PMID: 39768249 PMC: 11679507. DOI: 10.3390/life14121540.


Cereblon regulates the production of hepatic fibroblast growth factor 23 in diabetes.

An S, Nedumaran B, Oh H, Park T, Park C, Djalilian A BMB Rep. 2024; 57(12):533-538.

PMID: 39384178 PMC: 11693598.


Effects of High Dose Bolus Cholecalciferol on Free Vitamin D Metabolites, Bone Turnover Markers and Physical Function.

Bowles S, Jacques R, Hill T, Eastell R, Walsh J Nutrients. 2024; 16(17).

PMID: 39275206 PMC: 11397043. DOI: 10.3390/nu16172888.


Fibroblast Growth Factor 23 Neutralizing Antibody Ameliorates Abnormal Renal Phosphate Handling in Sickle Cell Disease Mice.

Xiao L, Clarke K, Hurley M Endocrinology. 2023; 164(12).

PMID: 37972265 PMC: 11032245. DOI: 10.1210/endocr/bqad173.


An integrated machine learning predictive scheme for longitudinal laboratory data to evaluate the factors determining renal function changes in patients with different chronic kidney disease stages.

Tsai M, Jhou M, Liu T, Fang Y, Lu C Front Med (Lausanne). 2023; 10:1155426.

PMID: 37859858 PMC: 10582636. DOI: 10.3389/fmed.2023.1155426.